Crinetics Pharmaceuticals Inc (CRNX) reported disappointing financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-1.38, falling short of Wall Street's consensus estimate of $-1.28 by $0.10. Revenue remained at $0.0B, matching expectations but indicating a lack of growth.
The announcement highlights challenges the company may face in its operational performance and market conditions. Investors will have the opportunity to gain further insights during the upcoming earnings conference call, scheduled for after market close.
Crinetics operates as a clinical-stage pharmaceutical company, focusing on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and related tumors. Its lead candidate, PALSONIFY (paltusotine), is in clinical development for conditions such as acromegaly and carcinoid syndrome associated with neuroendocrine tumors. The company is also developing Atumelnant for congenital adrenal hyperplasia and other endocrine disorders.
The company's current market capitalisation stands at $3,778.81, with a trailing twelve-month EPS of $-4.11. Looking ahead, Crinetics is set to report its next earnings on 4 August 2026, with an EPS estimate of $-1.3755 and revenue also expected to be $0.0B.